Valuation: Chugai Pharmaceutical Co., Ltd.

Market Cap 12,055B 74.21B 64.86B 59.99B 55.04B 104B 7,150B 106B 715B 281B 3,492B 279B 273B P/E 2026 *
23.7x
P/E 2027 * 20.3x
Enterprise Value 11,133B 68.53B 59.9B 55.4B 50.84B 96.21B 6,604B 97.88B 661B 260B 3,225B 257B 252B EV / Sales 2026 *
8.02x
EV / Sales 2027 * 7.09x
Free-Float
38.12%
Yield 2026 *
1.87%
Yield 2027 * 2.15%
1 day+1.16%
1 week-0.46%
Current month-2.77%
1 month-2.63%
3 months-14.74%
6 months-11.23%
Current year-11.14%
1 week 7,105
Extreme 7105
7,350
1 month 7,105
Extreme 7105
7,939
Current year 7,105
Extreme 7105
10,700
1 year 5,942
Extreme 5942
10,700
3 years 3,871
Extreme 3871
10,700
5 years 3,191
Extreme 3191
10,700
10 years 1,003.33
Extreme 1003.3333
10,700
Manager TitleAgeSince
Chief Executive Officer 63 01/03/2021
Director of Finance/CFO 59 28/03/2024
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 63 01/03/2020
Director/Board Member 59 28/03/2024
Director/Board Member 51 01/03/2025
Change 5-day change 1-year change 3-year change Capi.($)
+1.16%-0.46%+7.72%+89.18% 73.36B
+0.78%-0.59%+55.16%+164.25% 1,043B
+1.52%-1.23%+55.74%+59.56% 602B
+1.47%+4.27%+35.15%+91.86% 449B
+0.78%-0.71%+30.04%+24.61% 327B
+1.41%+0.58%+33.92%+47.20% 279B
-0.27%-1.87%+22.13%+23.47% 264B
-0.81%+2.11%+24.41%+62.86% 201B
+0.65%+6.22%+26.76%+77.99% 169B
-0.02%+4.20%+2.46%-29.77% 143B
Average +0.60%-0.78%+29.35%+61.12% 355.04B
Weighted average by Cap. +0.78%-1.81%+40.09%+85.59%

Financials

2026 *2027 *
Net sales 1,387B 8.54B 7.47B 6.9B 6.34B 11.99B 823B 12.2B 82.33B 32.34B 402B 32.07B 31.37B 1,535B 9.45B 8.26B 7.64B 7.01B 13.27B 911B 13.5B 91.1B 35.79B 445B 35.49B 34.71B
Net income 509B 3.13B 2.74B 2.53B 2.32B 4.4B 302B 4.47B 30.2B 11.86B 147B 11.76B 11.51B 593B 3.65B 3.19B 2.95B 2.71B 5.12B 352B 5.21B 35.18B 13.82B 172B 13.7B 13.4B
Net Debt -922B -5.68B -4.96B -4.59B -4.21B -7.97B -547B -8.11B -54.71B -21.49B -267B -21.31B -20.84B -1,164B -7.17B -6.26B -5.79B -5.32B -10.06B -690B -10.23B -69.08B -27.14B -337B -26.91B -26.32B
Logo Chugai Pharmaceutical Co., Ltd.
Chugai Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the research, development, manufacture, sale, import and export of pharmaceutical products. The pharmaceutical products and medical devices for patients include ACTEMRA, Avastin, ALAGLIO, Aresensa, Kadosaira, Gazaiba, Seruseputo, Zeruborafu, Zeroda, Taruseba, Tecentoriku, Pajeta and other products. The products are mainly applied to the treatment of cancer, kidney diseases, kidney transplantation, bone and joint diseases such as rheumatoid arthritis, osteoporosis, knee osteoarthritis and locomotive syndrome, influenza, hemophilia and other diseases. The Company is also engaged in the provision of management services, transportation and storage services, as well as drug information literature research services. The Company operates within the domestic market and to overseas markets, including Switzerland, United Kingdom, Germany, France, China, Singapore, Korea and the United States.
Employees
5,104
Date Price Change Volume
17/07/26 ¥7,325.00 +1.16% 2,964,200
16/07/26 ¥7,241.00 +1.59% 2,301,400
15/07/26 ¥7,128.00 -1.56% 2,330,400
14/07/26 ¥7,241.00 +0.15% 1,973,600
13/07/26 ¥7,230.00 -2.15% 2,054,100
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
15
Last Close Price
7,325.00JPY
Average target price
9,853.33JPY
Spread / Average Target
+34.52%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 4519 Stock